2. Induced Disease Models Products Immunology/Inflammation Anti-infection
  3. Immunology and Inflammatory Disease Models Cardiovascular System Disease Models Toll-like Receptor (TLR) HCV
  4. Myocarditis Models Heart Disease Models
  5. Resiquimod

Resiquimod  (Synonyms: R848; S28463)

Cat. No.: HY-13740 Purity: 99.87%
COA Handling Instructions

Molarity Calculator

Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

For research use only. We do not sell to patients.

Resiquimod Chemical Structure

Resiquimod Chemical Structure

CAS No. : 144875-48-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
5 mg USD 38 In-stock
10 mg USD 60 In-stock
25 mg USD 110 In-stock
50 mg USD 170 In-stock
100 mg USD 240 In-stock
500 mg USD 470 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 73 publication(s) in Google Scholar

Other Forms of Resiquimod:

Resiquimod Related Antibodies

Top Publications Citing Use of Products

70 Publications Citing Use of MCE Resiquimod

Proliferation Assay
RT-PCR
WB

    Resiquimod purchased from MedChemExpress. Usage Cited in: Cancer Gene Ther. 2023 Feb 13.  [Abstract]

    Resiquimod (10-200 μM) reduces E-cadherin and Wnt5a expression in a dose-dependent manner.

    Resiquimod purchased from MedChemExpress. Usage Cited in: Cytokine. 2017 Nov;99:310-315.  [Abstract]

    IL-23 production by macrophages after stimulation with LPS or Resiquimod M1 macrophages (day 9) were stimulated with LPS (10 ng) or Resiquimod (5 μM) for 6 h and IL-23 protein is measured by ELISA.

    Resiquimod purchased from MedChemExpress. Usage Cited in: J Interferon Cytokine Res. 2016 Sep;36(9):563-72.  [Abstract]

    With the stimulus of agonists LPS, ODN2006, Poly (I: C), and R848, the mRNA levels of goOASL in PBMCs are significantly upregulated in LPS- and Poly (I: C)-treated groups, and extremely upregulated in ODN2006- and R848-treated groups.

    View All Toll-like Receptor (TLR) Isoform Specific Products:

    View All Isoforms
    TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

    IC50 & Target

    TLR7

     

    TLR8

     

    In Vitro

    Resiquimod (R-848) induces both hapten- and allergen-specific circulating T cells, including TH2 effectors, to produce IFN-γ and even to lose the ability to produce IL-4[2].
    Resiquimod (R848) enhances PBL proliferation in a dose-dependent manner, and increases the number of BrdU-positive cells in BrdU incorporation assay. Cells treated with R848 exhibits significantly increased (3.5-fold) luciferase (a reporter of NF-κB activity) activity[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Resiquimod Related Antibodies
    In Vivo

    Resiquimod can be used to induce systemic lupus erythematosus models. Its pharmacokinetic characteristics feature a short half-life, a relatively low AUC at relevant doses, and a high Cmax[5].

    Induction of systemic Lupus erythematosus[4].
    Background
    Alterations in TLR signaling contributes to the initiation and/or exacerbation of lupus in humans and in murine models. Autoreactive B cells (in which TLR-7 activation occurs in response to RNA-containing antigens), in synergy with B cell receptor, undergo proliferation, isotype switching, and plasma cell differentiation, leading to the production of autoantibodies.
    Specific Mmodeling Methods
    Mice: Wild-type FVB/N, BALB/c, and C57BL/6 mice • female • 7-9 weeks old (period: 4 weeks)
    Administration: 100 μg • topical application to the right ear • three times a week for 4 weeks.
    Note
    (1) 100 μg of Resiquimod in 100 μL of Acetone.
    Modeling Indicators
    Metabolism changes: Elevates levels of autoantibodies to double-stranded DNA and multiple organ involvement, including glomerulonephritis, hepatitis, carditis.
    Histology analysis: Marked splenomegaly, and the liver revealed severe mononuclear cell infiltration around the portal veins and hepatocyte necrosis.
    Correlated Product(s): Myosin H Chain Fragment, mouse (HY-P2464)
    Opposite Product(s): Enpatoran (HY-134581)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Molecular Weight

    314.39

    Formula

    C17H22N4O2
    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    OC(C)(C)CN1C(COCC)=NC2=C1C3=CC=CC=C3N=C2N
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    Solvent & Solubility
    In Vitro: 

    DMF : 50 mg/mL (159.04 mM; Need ultrasonic)

    DMSO : ≥ 30 mg/mL (95.42 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Methanol : 25 mg/mL (79.52 mM; Need ultrasonic)

    Ethanol : 25 mg/mL (79.52 mM; Need ultrasonic)

    H2O : 0.1 mg/mL (0.32 mM; Need ultrasonic)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.1808 mL 15.9039 mL 31.8077 mL
    5 mM 0.6362 mL 3.1808 mL 6.3615 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% Saline

      Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution

    • Protocol 2

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (6.62 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.95%

    COA (254 KB) HNMR (202 KB) LCMS (119 KB)

    Handling Instructions (2659 KB)
    References
    Kinase Assay
    [3]

    For luciferase assay, FG-9307 cells are transfected with the firefly NF-κB-specific luciferase reporter vector pNFκB-Met-Luc2. Transfection efficiency is monitored by co-transfection with the pSEAP2 control vector, which constitutively expresses the human secreted enhanced alkaline phosphatase (SEAP). Then the cells are treated with Resiquimod (R848, 1 µg/mL), CQ (10 µM), CQ plus R848 or PBS and incubated at 22°C for 24 h. The culture medium of the transfectants is then analyzed for luciferase activity and SEAP activity using Luciferase Assay Kit and the Great EscAPe™ SEAP Chemiluminescence Detection Kit, respectively. The assay is performed three times.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Cell Assay
    [3]

    For inhibition of lysosomal acidification, cells are incubated with 10 µM CQ for 1 h before Resiquimod (R848) treatment. After treatment, 20 µL of 5 mg/mL MTT is added to the plate. The plate is incubated at 22°C for 4 h, and 200 µL dimethyl sulfoxide is added to the plate to dissolve the reduced formazan. The plate is then read at 490 nm with a microplate reader. To determine the effect of Myd88 inhibition on R848-induced cell proliferation, the Myd88 inhibitor Pepinh-MYD and the control peptide Pepinh-Control are added to PBL at the concentration of 50 µM, and the plate is incubated at 22°C for 6 h. After incubation, the cells are treated with R848 and subjected to MTT assay as above. To determine the effect of NF-κB inactivation on R848-induced cell proliferation, BAY-11-7082, an irreversible inhibitor of IκB-α phosphorylation, is added to the cells at the concentration of 1 µM, and the plate is incubated at 22°C for 1 h. After incubation, the cells are treated with R848 and subjected to MTT assay as earlier. All experiments are performed three times.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    A total of 40 SPF chickens of two-week old are allotted to one of the following four experimental groups (n=10/group): Group A: PBS control; Group B: inactivated NDV vaccine; Group C: commercial oil adjuvanted inactivated NDV vaccine prepared from lentogenic strain and Group D: combination of inactivated NDV vaccine and R-848 (50 μg/bird). Vaccine or PBS is administered by intramuscular route in the thigh muscle. A booster dose is given 14-day post immunization (d.p.i). Two weeks post-booster, experimental SPF birds are challenged with velogenic strain of NDV (105 ELD50 per bird) intramuscularly. Clinical signs and mortality are observed daily till 14 day post-challenge (d.p.c). Cloacal swabs (n=6/group) are collected from the birds on day 0, 4, 7 and 14 post-challenge and inoculated into 10-day old embryonated chicken eggs (n=3 eggs/sample) through intra-allantoic route. Three day post-inoculation, the allantoic fluid is checked for the NDV growth by spot haemagglutination using 10% chicken RBC.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Methanol / Ethanol / DMSO / DMF 1 mM 3.1808 mL 15.9039 mL 31.8077 mL 79.5193 mL
    5 mM 0.6362 mL 3.1808 mL 6.3615 mL 15.9039 mL
    10 mM 0.3181 mL 1.5904 mL 3.1808 mL 7.9519 mL
    15 mM 0.2121 mL 1.0603 mL 2.1205 mL 5.3013 mL
    20 mM 0.1590 mL 0.7952 mL 1.5904 mL 3.9760 mL
    25 mM 0.1272 mL 0.6362 mL 1.2723 mL 3.1808 mL
    30 mM 0.1060 mL 0.5301 mL 1.0603 mL 2.6506 mL
    40 mM 0.0795 mL 0.3976 mL 0.7952 mL 1.9880 mL
    50 mM 0.0636 mL 0.3181 mL 0.6362 mL 1.5904 mL
    60 mM 0.0530 mL 0.2651 mL 0.5301 mL 1.3253 mL
    DMSO / DMF 80 mM 0.0398 mL 0.1988 mL 0.3976 mL 0.9940 mL
    DMF 100 mM 0.0318 mL 0.1590 mL 0.3181 mL 0.7952 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Resiquimod Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Resiquimod144875-48-9R848 S28463R 848R-848S28463S 28463S-28463Toll-like Receptor (TLR)HCVHepatitis C virusInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Resiquimod
    Cat. No.:
    HY-13740
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.